
|Videos|July 7, 2020
Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer
Author(s)Targeted Oncology
Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Growing Alcohol-Attributable Cancer Burden in US Reveals Prevention Gap
2
INBRX-106/Pembrolizumab Shows Efficacy in First-Line HNSCC
3
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
4
Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC
5




































